|Articles|December 1, 2003

Raptiva Off and Running

San Francisco - A study on Raptiva (efalizumab) shows patients with moderate-to-severe plaque psoriasis who received 12 weeks of treatment experienced a significant reduction in signs and symptoms, and patients who continued treatment to 24 weeks continued to benefit.

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.

Latest CME